Allurion Reports First Quarter 2025 Financial Results and Provides Business Update
Financial Performance: Allurion Technologies reported a first-quarter revenue of $5.6 million, down from $9.4 million the previous year, while operating expenses decreased by 37% to $11.4 million, leading to a net operating loss reduction of 36% to $7.3 million.
Business Outlook: The company maintains its 2025 revenue guidance of approximately $30 million and is focused on expanding its Allurion Program, which aims to complement GLP-1 medications for weight loss, with plans for a prospective trial starting this year.
Trade with 70% Backtested Accuracy
Analyst Views on ALUR
About ALUR
About the author
Consumer Discretionary Stocks with Low Momentum and High Valuation
- Low Momentum Stocks: Allurion Technologies (ALUR) leads the consumer discretionary sector with an F momentum grade and a C valuation grade, indicating extremely weak price performance trends that could undermine investor confidence.
- Subsequent Rankings: Following closely are Duolingo (DUOL) and Lucid Group (LCID), both receiving an F momentum grade, suggesting similarly poor market performance that may lead to capital outflows.
- Overvaluation Risks: Sweetgreen (SG) and Venu Holding (VENU) are also listed with F momentum grades, achieving D+ and C valuation grades respectively, indicating that their market pricing may be excessively high and at risk of correction.
- Overall Market Trends: Bright Horizons Family Solutions (BFAM), DraftKings (DKNG), and Faraday Future Intelligent Electric (FFAI) all hold D- momentum grades, suggesting these companies face significant pressure in the current market environment, potentially impacting their future growth prospects.
Allurion Achieves 23% Weight Loss with Low-Dose Tirzepatide Combination
- Significant Weight Loss: After 12 months of treatment, 76 patients achieved an average weight loss of 23%, with lean body mass percentage increasing from 62% to 70%, demonstrating the effectiveness of the Allurion Program combined with low-dose tirzepatide, potentially setting a new treatment standard in the weight loss market.
- High Adherence Rates: All participants adhered to tirzepatide throughout the study, indicating that the lower dosing strategy effectively reduced side effects and discontinuation rates, enhancing the long-term weight loss potential and possibly changing the usage patterns of GLP-1 medications.
- Technological Innovation: The combination of Allurion's Smart Capsule and AI-powered Virtual Care Suite not only enhances patient treatment experiences but also optimizes weight loss outcomes through personalized monitoring and management, showcasing the company's technological leadership in the weight loss sector.
- Future Prospects: Allurion plans to validate these initial results in future clinical trials, and if successful, this could establish its market leadership in metabolically healthy weight loss, attracting further investment and partnership opportunities.
Zacks Industry Outlook Spotlights Boston Scientific, Insulet, BioLife Solutions, and Allurion
Industry Challenges: The medical products industry is facing significant challenges, including cost inflation from tariffs, supply-chain delays, and regulatory uncertainties, which are impacting margins and growth outlooks.
Resilience Through Innovation: Companies like Boston Scientific, Insulet, BioLife Solutions, and Allurion Technologies are navigating these challenges by focusing on innovation, operational efficiencies, and strategic acquisitions to drive organic growth.
Emerging Trends: Key trends shaping the industry include the integration of AI and digital health, a shift towards ambulatory and home-based care, advancements in robotics and specialty therapeutics, and evolving regulatory frameworks that emphasize value-based care.
Market Performance: The medical products industry has underperformed compared to the broader market, with a decline of 1.8% over the past year, while companies are still positioned for potential growth through strategic investments and improved operational practices.
Allurion Technologies, Inc. (ALUR) Announces Q2 Loss and Falls Short of Revenue Projections
Quarterly Performance: Allurion Technologies, Inc. reported a quarterly loss of $0.57 per share, better than the expected loss of $0.65, but down from earnings of $0.25 per share a year ago.
Revenue Miss: The company generated revenues of $3.38 million for the quarter, missing estimates by 43.21% and significantly lower than $11.77 million from the previous year.
Stock Outlook: Allurion's shares have dropped about 78% this year, with current consensus EPS estimates indicating continued losses; the stock holds a Zacks Rank #4 (Sell), suggesting it may underperform in the near future.
Industry Context: The Medical - Products industry ranks in the top 39% of Zacks industries, which could influence Allurion's performance, while Agilent Technologies is set to report its results soon, with expectations of modest growth.
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS
AI-Powered Allurion Program Findings: Recent studies presented at the ASMBS 2025 Annual Meeting demonstrate that the Allurion Program effectively promotes metabolically healthy weight loss, showing significant fat loss and muscle mass preservation in nearly 20,000 patients over four years.
Long-Term Weight Loss Maintenance: The program has shown an average weight loss maintenance of 89% after four years, highlighting its potential as a sustainable, non-invasive solution for obesity management without the need for surgery.
Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program
Study Results: A study presented at the SOFFCO.MM meeting showed that 1,962 patients in France using the Allurion Program experienced an average weight loss of 12.2%, with muscle mass increasing by 6.6% and fat mass decreasing by 11% after four months.
Resumption of Services: Allurion Technologies announced the resumption of shipments to France and plans to restart patient treatments next month, emphasizing their commitment to metabolically healthy weight loss solutions.
Consumer Discretionary Stocks with Low Momentum and High Valuation
- Low Momentum Stocks: Allurion Technologies (ALUR) leads the consumer discretionary sector with an F momentum grade and a C valuation grade, indicating extremely weak price performance trends that could undermine investor confidence.
- Subsequent Rankings: Following closely are Duolingo (DUOL) and Lucid Group (LCID), both receiving an F momentum grade, suggesting similarly poor market performance that may lead to capital outflows.
- Overvaluation Risks: Sweetgreen (SG) and Venu Holding (VENU) are also listed with F momentum grades, achieving D+ and C valuation grades respectively, indicating that their market pricing may be excessively high and at risk of correction.
- Overall Market Trends: Bright Horizons Family Solutions (BFAM), DraftKings (DKNG), and Faraday Future Intelligent Electric (FFAI) all hold D- momentum grades, suggesting these companies face significant pressure in the current market environment, potentially impacting their future growth prospects.
Allurion Achieves 23% Weight Loss with Low-Dose Tirzepatide Combination
- Significant Weight Loss: After 12 months of treatment, 76 patients achieved an average weight loss of 23%, with lean body mass percentage increasing from 62% to 70%, demonstrating the effectiveness of the Allurion Program combined with low-dose tirzepatide, potentially setting a new treatment standard in the weight loss market.
- High Adherence Rates: All participants adhered to tirzepatide throughout the study, indicating that the lower dosing strategy effectively reduced side effects and discontinuation rates, enhancing the long-term weight loss potential and possibly changing the usage patterns of GLP-1 medications.
- Technological Innovation: The combination of Allurion's Smart Capsule and AI-powered Virtual Care Suite not only enhances patient treatment experiences but also optimizes weight loss outcomes through personalized monitoring and management, showcasing the company's technological leadership in the weight loss sector.
- Future Prospects: Allurion plans to validate these initial results in future clinical trials, and if successful, this could establish its market leadership in metabolically healthy weight loss, attracting further investment and partnership opportunities.
Zacks Industry Outlook Spotlights Boston Scientific, Insulet, BioLife Solutions, and Allurion
Industry Challenges: The medical products industry is facing significant challenges, including cost inflation from tariffs, supply-chain delays, and regulatory uncertainties, which are impacting margins and growth outlooks.
Resilience Through Innovation: Companies like Boston Scientific, Insulet, BioLife Solutions, and Allurion Technologies are navigating these challenges by focusing on innovation, operational efficiencies, and strategic acquisitions to drive organic growth.
Emerging Trends: Key trends shaping the industry include the integration of AI and digital health, a shift towards ambulatory and home-based care, advancements in robotics and specialty therapeutics, and evolving regulatory frameworks that emphasize value-based care.
Market Performance: The medical products industry has underperformed compared to the broader market, with a decline of 1.8% over the past year, while companies are still positioned for potential growth through strategic investments and improved operational practices.
Allurion Technologies, Inc. (ALUR) Announces Q2 Loss and Falls Short of Revenue Projections
Quarterly Performance: Allurion Technologies, Inc. reported a quarterly loss of $0.57 per share, better than the expected loss of $0.65, but down from earnings of $0.25 per share a year ago.
Revenue Miss: The company generated revenues of $3.38 million for the quarter, missing estimates by 43.21% and significantly lower than $11.77 million from the previous year.
Stock Outlook: Allurion's shares have dropped about 78% this year, with current consensus EPS estimates indicating continued losses; the stock holds a Zacks Rank #4 (Sell), suggesting it may underperform in the near future.
Industry Context: The Medical - Products industry ranks in the top 39% of Zacks industries, which could influence Allurion's performance, while Agilent Technologies is set to report its results soon, with expectations of modest growth.
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS
AI-Powered Allurion Program Findings: Recent studies presented at the ASMBS 2025 Annual Meeting demonstrate that the Allurion Program effectively promotes metabolically healthy weight loss, showing significant fat loss and muscle mass preservation in nearly 20,000 patients over four years.
Long-Term Weight Loss Maintenance: The program has shown an average weight loss maintenance of 89% after four years, highlighting its potential as a sustainable, non-invasive solution for obesity management without the need for surgery.
Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program
Study Results: A study presented at the SOFFCO.MM meeting showed that 1,962 patients in France using the Allurion Program experienced an average weight loss of 12.2%, with muscle mass increasing by 6.6% and fat mass decreasing by 11% after four months.
Resumption of Services: Allurion Technologies announced the resumption of shipments to France and plans to restart patient treatments next month, emphasizing their commitment to metabolically healthy weight loss solutions.
